Pravastatin and olmesartan synergistically ameliorate renal failure-induced vascular calcification

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 9, 2014, Pages 917-929

  Iijima, Katsuya ^a,b   Ito, Yuki ^b   Son, Bo Kyung ^b   Akishita, Masahiro ^b   Ouchi, Yasuyoshi ^b,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TORANOMON HOSPITAL   (Japan)

Author keywords

ARB; Chronic kidney disease; Combination therapy; Statin; Vascular calcification

Indexed keywords

CALCIUM; GROWTH ARREST SPECIFIC PROTEIN 6; OLMESARTAN; PHOSPHORUS; PRAVASTATIN; PROTEIN KINASE B; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL CALCIFICATION; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG POTENTIATION; HISTOLOGY; KIDNEY FAILURE; LOW DRUG DOSE; MALE; NICK END LABELING; NONHUMAN; PLEIOTROPY; POLYACRYLAMIDE GEL ELECTROPHORESIS; RAT; ULTRASOUND; ANIMAL; BLOOD PRESSURE; CALCINOSIS; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; PATHOLOGY; WISTAR RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOPTOSIS; BLOOD PRESSURE; CALCINOSIS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMIDAZOLES; MALE; PRAVASTATIN; RATS; RATS, WISTAR; RENAL INSUFFICIENCY; TETRAZOLES;

EID: 84907511863     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.23218     Document Type: Article

References (46)

1. Abedin M, Tintut Y, Demer LL: Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol, 2004; 24: 1161-1170
2. Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M: Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol, 1996; 16: 978-983
3. Dao HH, Essalihi R, Bouvet C, Moreau P: Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res, 2005; 66: 307-317
4. Cozzolino M, Dusso AS, Slatopolsky E: Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol, 2001; 12: 2511-2516
5. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant, 2000; 15: 218-223
6. Giachelli CM: Ectopic calcification: gathering hard facts about soft tissue mineralization. Am J Pathol, 1999; 154: 671-675
7. Shanahan CM, Cary NR, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME: Medial localization of mineralization-regulating proteins in association with Monckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation, 1999; 100: 2168-2176
8. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM: Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol, 2003; 23: 489-494
9. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res, 2000; 87: E10-17
10. Davignon J: Beneficial cardiovascular pleiotropic effects of statins. Circulation, 2004; 109: Ⅲ39-Ⅲ43
11. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele, de Strihou C, Miyata T: Reno-protective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol, 2005; 16: 3631-3641
12. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003; 361: 1149-1158
13. Son BK, Kozaki K, Iijima K, Eto M, Kojima T, Ota H, Senda Y, Maemura K, Nakano T, Akishita M, Ouchi Y: Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway. Circ Res, 2006; 98: 1024-1031
14. Yokozawa T, Zheng PD, Oura H, Koizumi F: Animal model of adenine-induced chronic renal failure in rats. Nephron, 1986; 44: 230-234
15. Ikizler TA: Epidemiology of vascular disease in renal failure. Blood Purif, 2002; 20: 6-10
16. Johnson RC, Leopold JA, Loscalzo J: Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res, 2006; 99: 1044-1059
17. Toussaint ND, Kerr PG: Vascular calcification and arterial stiffness in chronic kidney disease: Implications and management. Nephrology, 2007; 12: 500-509
18. Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O’Brien KD: HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet, 2002; 359: 1125-1126
19. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP: Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation, 2001; 104: 2205-2209
20. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ: Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med, 1998; 339: 1972-1978
21. Achenbach S, Ropers D, Pohle K, Leber A, Thilo C, Knez A, Menendez T, Maeffert R, Kusus M, Regenfus M, Bickel A, Haberl R, Steinbeck G, Moshage W, Daniel WG: Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation, 2002; 106: 1077-1082
22. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med, 2005; 352: 2389-2397
23. Takenaka T, Takane H, Kikuta T, Watanabe Y, Suzuki H: Statin improves flow-mediated vasodilation in chronic kidney diseases. Int J Hypertens, 2013; 2013: 876865
24. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int, 2001; 59: 260-269
25. Tonelli M, Moyé L, Sacks FM, Cole T, Curhan GC; Cholesterol and Recurrent Events Trial Investigators: CARE trial investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol, 2003; 14: 1605-1613
26. Kasahara M, Nakagawa T, Yokoi H, Kuwabara T, Yasuno S, Mori K, Mukoyama M, Ueshima K: Do statins play a role in renoprotection? Clin Exp Nephrol, 2014 [Epub ahead of print]
27. Suzuki H, Watanabe Y, Kumagai H, Shuto H: Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Ther Adv Cardiovasc Dis, 2013; 7: 306-315
28. Verma A, Ranganna KM, Reddy RS, Verma M, Gordon NF: Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol, 2005; 96: 1290-1292
29. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB: Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis, 2002; 39: 1213-1217
30. Koh KK: Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res, 2000; 47: 648-657
31. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele, de Strihou C, Miyata T: Reno-protective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol, 2005; 16: 3631-3641
32. Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, Shin MS, Ahn TH, Choi IS, Shin EK: Pleiotropic effects of angiotensin Ⅱ receptor blocker in hypertensive patients. J Am Coll Cardiol, 2003; 42: 905-910
33. Karalliedde J, Smith A, DeAngelis L, Mirenda V, Kandra A, Botha J, Ferber P, Viberti G: Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension, 2008; 51: 1617-2163
34. Agata J, Nagahara D, Kinoshita S, Takagawa Y, Moniwa N, Yoshida D, Ura N, Shimamoto K: Angiotensin Ⅱ receptor blocker prevents increased arterial stiffness in patients with essential hypertension. Circ J, 2004; 68: 1194-1198
35. Ono T, Sanai T, Miyahara Y, Noda R: Olmesartan is More Effective Than Other Angiotensin Receptor Antagonists in Reducing Proteinuria in Patients With Chronic Kidney Disease Other Than Diabetic Nephropathy. Curr Ther Res Clin Exp, 2013; 74: 62-67
36. Yanagi M, Tamura K, Fujikawa T, Wakui H, Kanaoka T, Ohsawa M, Azushima K, Maeda A, Kobori H, Umemura S: The angiotensin Ⅱ type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease. Hypertens Res, 2013; 36: 262-269
37. Sakai Y, Suzuki A, Mugishima K, Sumi Y, Otsuka Y, Otsuka T, Ohno D, Murasawa T, Tsuruoka S: Comparison of once daily versus twice daily olmesartan in patients with chronic kidney disease. Int J Nephrol Renovasc Dis, 2013; 6: 223-227
38. Moriyama T, Tsuruta Y, Kojima C, Itabashi M, Sugiura H, Takei T, Ogawa T, Uchida K, Tsuchiya K, Nitta K: Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease. Int Urol Nephrol, 2012; 44: 841-845
39. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Kang MH, Ahn TH, Choi IS, Shin EK: Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation, 2004; 110: 3687-3692
40. Rodriguez-Iturbe B, Sato T, Quiroz Y, Vaziri ND: AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia, and glomerulosclerosis in the Imai rat. Kidney Int, 2004; 66: 668-675
41. Chen M, Ichiki T, Ohtsubo H, Imayama I, Inanaga K, Miyazaki R, Sunagawa K: Inhibition of balloon injury-induced neointimal formation by olmesartan and pravastatin in rats with insulin resistance. Hypertens Res, 2007; 30: 971-978
42. Koh KK, Cardillo C, Bui MN, Hathaway L, Csako G, Waclawiw MA, Panza JA, Cannon RO III: Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation, 1999; 99: 354-360
43. Schiffrin EL, Park JB, Intengan HD, Touyz RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation, 2000; 101: 1653-1659
44. Wassmann S, Hilgers S, Laufs U, Böhm M, Nickenig G: Angiotensin Ⅱ type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol, 2002; 22: 1208-1212
45. Coladonato JA: Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol, 2005; 16: S107-114
46. Son BK, Akishita M, Iijima K, Ogawa S, Arai T, Ishii H, Maemura K, Aburatani H, Eto M, Ouchi Y: Thrombomodulin, a novel molecule regulating inorganic phosphate-induced vascular smooth muscle cell calcification. J Mol Cell Cardiol, 2013; 56: 72-80